1 – 40 of 40
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
- AAV Production Everywhere : A Simple, Fast, and Reliable Protocol for In-house AAV Vector Production Based on Chloroform Extraction (
- 2019
- Practical Considerations for the Use of DREADD and Other Chemogenetic Receptors to Regulate Neuronal Activity in the Mammalian Brain (
- Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease (
- Seeding of protein aggregation causes cognitive impairment in rat model of cortical synucleinopathy (
- A systematic capsid evolution approach performed in vivo for the design of AAV vectors with tailored properties and tropism (
- 2018
- Molecular barcoding of viral vectors enables mapping and optimization of mRNA trans-splicing (
- Chemogenetic modulation of cholinergic interneurons reveals their regulating role on the direct and indirect output pathways from the striatum (
- Repairing the brain : Gene therapy (
- A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency (
- 2016
- Expression of Multiple Functional RNAs or Proteins from One Viral Vector. (
- Identification of multiple QTLs linked to neuropathology in the engrailed-1 heterozygous mouse model of Parkinson's disease (
- Cellular Barcoding Links B-1a B Cell Potential to a Fetal Hematopoietic Stem Cell State at the Single-Cell Level (
- A novel process of viral vector barcoding and library preparation enables high-diversity library generation and recombination-free paired-end sequencing (
- DREADD Modulation of Transplanted DA Neurons Reveals a Novel Parkinsonian Dyskinesia Mechanism Mediated by the Serotonin 5-HT6 Receptor (
- 2014
- Novel AAV-Based Rat Model of Forebrain Synucleinopathy Shows Extensive Pathologies and Progressive Loss of Cholinergic Interneurons. (
- Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. (
- 2013
- Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. (
- A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP. (
- 2012
- Dysregulated dopamine storage increases the vulnerability to alpha-synuclein in nigral neurons (
- Design of a Single AAV Vector for Coexpression of TH and GCH1 to Establish Continuous DOPA Synthesis in a Rat Model of Parkinson's Disease. (
- 2011
- Gene therapy for Parkinson's disease shows promise. (
- Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. (
- 2010
- A General Chemical Method to Regulate Protein Stability in the Mammalian Central Nervous System (
- Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates (
- Gene therapy for dopamine replacement. (
- Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. (
- Gene therapy for Parkinson's disease. (
- 2009
- Dose Optimization for Long-term rAAV-mediated RNA Interference in the Nigrostriatal Projection Neurons. (
- Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats (
- Gene therapy by enzyme replacement for Parkinson’s disease Optimization of continuous DOPA delivery and development of a candidate vector for clinical application (
- Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene Therapy (
- Gene therapy for dopamine replacement in Parkinson's disease. (
- Scientific rationale for the development of gene therapy strategies for Parkinson's disease. (
- 2008
- In vivo gene delivery for development of mammalian models for Parkinson's disease (
- Applications of lentiviral vectors for biology and gene therapy of neurological disorders. (
- Future Cell- and Gene-Based Therapies for Parkinson's Disease (
- 2007
- Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. (
- Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. (
- 2006
- Morphometric and psychometric comparisons between non-substance-abusing patients with posttraumatic stress disorder and normal controls (
- 2005
- Imaging in cell-based therapy for neurodegenerative diseases. (